The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

Karasavvas, Nicos; Billings, Erik; Rao, Mangala; Williams, Constance; Zolla‐Pazner, Susan; T. Bailer, Robert; A. Koup, Richard; Madnote, Sirinan; Arworn, Duangnapa; Shen, Xiaoying; D. Tomaras, Georgia; R. Currier, Jeffrey; Jiang, Mike; A. Magaret, Craig; Andrews, Charla; Gottardo, Raphaël; B. Gilbert, Peter; Cardozo, Timothy; Rerks‐Ngarm, Supachai; Nitayaphan, Sorachai; Pitisuttithum, Punnee; Kaewkungwal, Jaranit; Paris, Robert; Greene, Kelli; Gao, Hongmei; Gurunathan, Sanjay; Tartaglia, Jim; Sinangil, Faruk; Korber, Bette; C. Montefiori, David; R. Mascola, John; L. Robb, Merlin; F. Haynes, Barton; Ngauy, Viseth; L. Michael, Nelson; H. Kim, Jérôme

doi:10.1089/aid.2012.0103

Public

The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

Published in AIDS Research and Human Retroviruses • Oct 4, 2012

Authors:

Nicos Karasavvas

Erik Billings

Mangala Rao

Abstract

The Thai Phase III clinical trial (RV144) showed modest efficacy in preventing HIV-1 acquisition. Plasma collected from HIV-1-uninfected trial participants completing all injections with ALVAC-HIV (vCP1521) prime and AIDSVAX B/E boost were tested for antibody responses against HIV-1 gp120 envelope (...

Subject

Antibody

V3 loop

Virology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!